Cancer-drug J/V deal may be worth almost $1B article from Los Angeles Business from bizjournals

Los Angeles Business from bizjournals

This story was sent to you by Jeffrey Allen (ir@globalcrossroadscapital.com):

Micromet deal with Amgen could reap $976 million

Published: July 11, 2011

Micromet Inc.bizWatch

Micromet Inc.

Latest from The Business Journals

Micromet deal with Amgen could reap 6 millionMicromet trial sees 75% cancer remissionMicromet raises M, stock falls

Follow this company


has inked a cancer drug development deal with Amgen Inc.bizWatch

Amgen Inc.

Latest from The Business Journals

Micromet deal with Amgen could reap 6 millionSacramento planning high-profile bike raceArray BioPharma cuts staff by 20%

Follow this company


that could be worth an eye-popping $976 million. Micromet had 2011 first quarter revenue of $5.5 million and revenue for all of 2010 of $28.7 million.

View full article

Copyright (C) American City Business Journals Inc. All rights reserved.
bizjournals digital network

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s